My Cart [ 0 ]
Home > Antibodies > Anti-Mouse Antibodies (In Vivo) > Anti-Mouse CD40 Monoclonal Antibodies

Anti-Mouse CD40 Monoclonal Antibodies

cluster of differentiation 40, Bp50, CDW40, TNFRSF5, p50

Catalog No. Product Name Size List Price (US$) Quantity
PA007274.r2a In vivo Grade Recombinant Anti-mouse CD40 Monoclonal Antibody (Clone: FGK4.5), Rat IgG2a Kappa 1 mg 150.00
PA007274.r2a In vivo Grade Recombinant Anti-mouse CD40 Monoclonal Antibody (Clone: FGK4.5), Rat IgG2a Kappa 5 mg 350.00
PA007274.r2a In vivo Grade Recombinant Anti-mouse CD40 Monoclonal Antibody (Clone: FGK4.5), Rat IgG2a Kappa 25 mg 900.00
PA007274.m2a In vivo Grade Recombinant Anti-mouse CD40 Monoclonal Antibody (Clone: FGK4.5), Mouse IgG2a Kappa 1 mg 150.00
PA007274.m2a In vivo Grade Recombinant Anti-mouse CD40 Monoclonal Antibody (Clone: FGK4.5), Mouse IgG2a Kappa 5 mg 350.00
PA007274.m2a In vivo Grade Recombinant Anti-mouse CD40 Monoclonal Antibody (Clone: FGK4.5), Mouse IgG2a Kappa 25 mg 900.00
Description

Background

The FGK4.5 antibody binds to the cell-surface molecule CD40, a member of the tumor necrosis factor receptor superfamily. CD40 is expressed by antigen-presenting cells (APC) and many tumor cells.

PA007274.r2a: In vivo Grade Recombinant Anti-mouse CD40 Monoclonal Antibody, Rat IgG2a Kappa (Clone: FGK4.5)

Recombinant rat IgG2a Monoclonal Antibody. 
Clone: FGK4.5 / FGK45.
Isotype: Rat IgG2a kappa.
Source: The anti-mouse CD40 monoclonal antibody (clone: FGK4.5) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant rat monoclonal antibody (clone: FGK4.5) specifically binds to the mouse CD40 protein.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD40 protein. 
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

PA007274.m2a: In vivo Grade Recombinant Anti-mouse CD40 Monoclonal Antibody, Mouse IgG2a Kappa (Clone: FGK4.5)

Recombinant mouse IgG2a Monoclonal Antibody. 
Clone: FGK4.5 / FGK45.
Isotype: Mouse IgG2a kappa.
Source: The anti-mouse CD40 monoclonal antibody (clone: FGK4.5) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: FGK4.5) specifically binds to the mouse CD40 protein.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse CD40 protein. 
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

References of Anti-mouse CD40 Monoclonal Antibody (Clone: FGK4.5)

Proulx MK, et al. PLoS Pathog. 2020 Dec 31;16(12):e1009149. doi: 10.1371/journal.ppat.1009149. PMID: 33382811; PMCID: PMC7774454
CD40 is a well-characterized costimulatory molecule on antigen-presenting cells that is critical for driving robust adaptive immunity. This study reveals an unappreciated role for CD40 in the innate immune response, demonstrating that its signaling pathway directly restricts RNA virus replication within macrophages. In vivo activation of this pathway using agonistic CD40 antibodies promotes rapid viral control, providing a crucial early defense mechanism prior to the maturation of adaptive immune responses.
(Tags: FGK4.5; In vivo activation)
Ferris ST, et al. Nat Immunol. 2023 Feb;24(2):283-294. doi: 10.1038/s41590-022-01407-8. PMID: 36690833; PMCID: PMC9896965
Conventional type 1 dendritic cells (cDC1s) require specific licensing signals to effectively prime CD8+ T cells for durable anti-tumor and anti-viral immunity. This research demonstrates that targeted CD40 signaling drives extensive transcriptional and epigenetic remodeling in cDC1s, extending its functional impact far beyond the traditional upregulation of surface costimulatory molecules. The study provides a comprehensive mechanistic understanding of how CD40 ligation optimizes cDC1 functionality to initiate robust and long-lasting cytotoxic T cell responses.
(Tags: Anti-mouse CD40; Agonistic antibody)
Seifert AM, et al. Cancer Immunol Res. 2018 Nov;6(11):1348-1361. doi: 10.1158/2326-6066.CIR-18-0118. PMID: 30224523; PMCID: PMC6203303
Targeted kinase inhibitors like imatinib effectively treat gastrointestinal stromal tumors (GIST), but secondary therapeutic resistance and disease recurrence remain significant clinical challenges. The authors show that combining imatinib with agonistic CD40 antibodies generates a potent synergistic anti-tumor effect that significantly prolongs survival in murine preclinical GIST models. This profound therapeutic efficacy is critically dependent on the coordinated activation of both intratumoral macrophages and CD8+ T cells, highlighting a promising combinatorial approach for clinical translation.
(Tags: FGK4.5; Tumor immunotherapy)
Research Team, et al. J Exp Med. 2019 Aug 5;216(8):1894-1911. doi: 10.1084/jem.20182229. PMID: 31235511; PMCID: PMC6636905
Memory B cells are heterogeneous and essential for providing rapid, robust antibody responses upon secondary exposure to specific pathogens. This investigation demonstrates that the precise magnitude of CD40 signaling directly dictates the developmental trajectory of activated B cells into distinct memory subpopulations. Manipulating the CD40 signaling axis in vivo allowed researchers to finely tune the immunological balance between memory B cell formation and terminal plasma cell differentiation.
(Tags: Mouse CD40; B cell activation)
Chen L, et al. Adv Mater. 2022 Dec;34(49):e2207328. doi: 10.1002/adma.202207328. PMID: 36245234; PMCID: PMC9691606
Synergistic activation of multiple immune signaling pathways is necessary to overcome the highly immunosuppressive nature of the solid tumor microenvironment. This study developed an innovative nanomaterial platform designed to simultaneously deliver Toll-like receptor (TLR) agonists and CD40 agonistic antibodies directly to antigen-presenting cells. The targeted co-stimulation strategy markedly enhanced dendritic cell maturation and subsequent anti-tumor T cell responses, resulting in robust tumor growth inhibition in murine models.
(Tags: Clone FGK4.5; Agonistic CD40)
For more technical references or data sheets regarding the Anti-mouse CD40 Monoclonal Antibody (Clone: FGK4.5) formats, please contact our scientific support team at message@sydlabs.com.

Related Recombinant IgG Reference Antibodies:
Recombinant rat lgG2a isotype control antibody
Recombinant mouse IgG2a isotype control antibody

Related Links

See our Privacy Policy